BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics in 2023 and the drug's approval last September ended a decades-long drought in new-mechanism therapies for ...

A high-level overview of Karyopharm Therapeutics Inc. (KPTI) stock. View (KPTI) real-time stock price, chart, news, analysis, analyst reviews and more.

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for ...

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.